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The suppressor of cytokine signaling (SOCS) proteins are
negative regulators of the JAK/STAT pathway activated by pro-
inflammatory cytokines, including the tumor necrosis factor-
(TNF-). SOCS3 is also implicated in hypertriglyceridemia
associated to insulin resistance. Proprotein convertase subtili-
sin kexin type 9 (PCSK9) levels are frequently found to be posi-
tively correlated to insulin resistance and plasma very low
density lipoprotein (VLDL) triglycerides concentrations. The
present study aimed to investigate the possible role of TNF-
and JAK/STAT pathway on de novo lipogenesis and PCSK9
expression in HepG2 cells. TNF- induced both SOCS3 and
PCSK9 in a concentration-dependent manner. This effect was
inhibited by transfection with siRNA anti-STAT3, suggesting
the involvement of the JAK/STAT pathway. Retroviral overex-
pression of SOCS3 inHepG2 cells (HepG2SOCS3) strongly inhib-
ited STAT3 phosphorylation and induced PCSK9 mRNA and
protein, with no effect on its promoter activity and mRNA sta-
bility. Consistently, siRNA anti-SOCS3 reduced PCSK9 mRNA
levels, whereas an opposite effect was observedwith siRNAanti-
STAT3. In addition, HepG2SOCS3 express higher mRNA levels
of key enzymes involved in thede novo lipogenesis, such as fatty-
acid synthase, stearoyl-CoA desaturase (SCD)-1, and apoB.
These responses were associated with a significant increase of
SCD-1 protein, activation of sterol regulatory element-binding
protein-1c (SREBP-1), accumulation of cellular triglycerides,
and secretion of apoB. HepG2SOCS3 show lower phosphoryla-
tion levels of insulin receptor substrate 1 (IRS-1) Tyr896 andAkt
Ser473 in response to insulin. Finally, insulin stimulation pro-
duced an additive effect with SOCS3 overexpression, further
inducing PCSK9, SREBP-1, fatty acid synthase, and apoB
mRNA. In conclusion, our data candidate PCSK9 as a gene
involved in lipid metabolism regulated by proinflammatory
cytokine TNF- in a SOCS3-dependent manner.
The family of suppressor of cytokine signaling (SOCS)2 con-
sists of eight members (SOCS-1 to SOCS-7 and cytokine-in-
ducible SH2 protein (CIS) all sharing a central SH2 domain and
a C-terminal SOCS box. Expression of CIS, SOCS-1, SOCS-2,
and SOCS-3 is induced by various cytokines, including IL-6 and
tumor necrosis factor- (TNF-) (1), and has been implicated
in the negative regulation of several pathways, particularly the
Janus kinase (JAK) signal transducer and activator of transcrip-
tion (STAT) one (2). SOCS proteins are highly and selectively
induced in a tissue-specificmanner by a diverse range of stimuli
other than the classical activators of the JAK/STAT pathway,
including insulin (3), leptin (4), and resistin (5). In obesity, the
expression of SOCS proteins is elevated in a variety of tissues
that are vital for regulating fatty acid (FA)metabolism and insu-
lin sensitivity. For instance, SOCS1 and SOCS3 are up-regu-
lated in the liver of obese diabetic db/dbmice and other insulin
resistance (IR)models such as ob/obmice andmice fed high fat
diet (6, 7). The functional role of SOCS3 on hepatic steatosis
and hyperlipidemiawas also demonstrated by using SOCS anti-
sense approach. The latter reduced in db/db mice the elevated
hepatic lipid content and plasma triglycerides close to the nor-
mal observed in control mice (7). Furthermore, liver of mor-
bidly obese subjects exhibits higher expression of SOCS3 pro-
tein and attenuated JAK/STAT signaling, resulting in enhanced
sterol regulatory element-binding protein-1c (SREBP-1c) tran-
scriptional activity, a key regulator of de novo lipid biosynthesis
(8). This evidence might suggest that the inhibition of JAK/
STAT pathway by SOCS3 is mechanistically related to the
development of hepatic IR and dyslipidemia in humans.
Proprotein convertase subtilisin kexin type 9 (PCSK9)
belongs to the proprotein convertase family (9). Genetic and,
more recently, pharmacological studies have clearly demon-
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strated its involvement in the regulation of low density lipopro-
tein cholesterol (LDL) levels by inducing the degradation of the
LDL receptor (LDLR) in a manner independent from its pro-
teolytic activity (10–13). Similarly to the genes involved in the
regulation of the cholesterol homeostasis, i.e. hydroxyl-methyl-
glutaryl-CoA reductase and synthase and the LDLR, PCSK9 is
under the control of the SREBP-2 (14). For this reason the phar-
macological activation of the SREBP pathway by HMG-CoA
reductase inhibitors, statins, induces PCSK9 both in experi-
mental and clinical settings (15–17). Although SREBP-1a and
SREBP-1c preferentially activate genes involved in the synthe-
sis of fatty acids and triglycerides, their homologous SREBP-2
preferentially transcribes for genes involved in the cholesterol
biosynthetic pathway (18, 19). To this regard, PCSK9 appears to
be regulated by both SREBP-2 and SREBP-1c (14, 20), where the
latter mediates the induction of PCSK9 in response to insulin
(14, 21–23). The involvement of SREBP-1c in the regulation of
PCSK9 levels has also been observed in humans, where PCSK9
levels positively correlated with IR, liver steatosis, and very low
density lipoprotein (VLDL-TG) triglycerides (TG) (24).
This evidence suggests that, although PCSK9 is an important
regulator of LDL-C levels, it could also be implicated in the
homeostasis of TG-rich lipoproteins. It is, indeed, of interest
that the association between plasma PCSK9 and LDL-C is weak
and has been estimated to account for only the 7% of the vari-
ations in LDL-C (25), whereas PCSK9 levels are more signifi-
cantly associated with plasma concentrations of TG, glucose,
and insulin (21, 25–27). Based on these premises, the present
study aimed to investigate the possible role of TNF- and JAK/
STATpathway onde novo lipogenesis andPCSK9 expression in
the human HepG2 cell line.
Experimental Procedures
Cell Cultures—The Human hepatocellular liver carcinoma
cell line, HepG2, was cultured in 10% FCS/MEM supplemented
with penicillin (10,000 units/ml), streptomycin (10 mg/ml),
nonessential amino acids, and sodium pyruvate. For the exper-
iments, cells were incubated with MEM containing either 10%
of lipoprotein plasma-deprived serum (LPDS) or 10% fetal calf
serum (FCS) as indicated in the figures legend.
Reagents and Antibodies—MEM, trypsin EDTA, penicillin,
streptomycin, nonessential amino acid solution, FCS, dispos-
able culture flasks, and Petri dishes were from Euroclone (Pero,
Milan, Italy), and filters were from Millipore (Billerica, MA).
Molecular weight protein standards were from Bio-Rad. SDS,
TEMED, ammonium persulfate, glycine, and acrylamide solu-
tion (30% T, 2.6% C) were obtained from Bio-Rad. BCA assay
for determination of protein concentrations was purchased
from Thermo Fischer Scientific (Waltham, MA). [14C]Acetate
was from Amersham Biosciences. Recombinant insulin,
TNF-, and bovine serum albumin (BSA) were purchased from
Sigma. STAT3 inhibitor, MD77, was kindly provided by Prof.
Daniela Barlocco (Università degli Studi diMilano,Milan, Italy)
31. The JAK inhibitor JAK1was purchased fromMillipore (Mil-
lipore, Milan, Italy). Actinomycin D was purchased from
Abcam (Cambridge, UK), and fatostatin hydrobromide and
25-hydroxycholesterol (25-OH cholesterol) were from Sigma.
For Western blot (WB) analysis, the following antibodies were
used: anti-PCSK9 and anti-SREBP-2 (Cayman, Tallinn, Esto-
nia), anti--tubulin (Sigma), anti-pAKT (Millipore), anti-AKT
and anti-SOCS3 (Cell Signaling Technology, Danver, MA),
anti-pSTAT3, anti-insulin receptor substrate (pIRS-1), anti-
stearoyl-CoA desaturase (SCD-1), and anti-hepatocyte nuclear
factor (HNF)-1 (Abcam), anti-STAT3 and SREBP-1 (Santa-
Cruz Biotechnology, Santa Cruz, CA), and anti-mouse and
anti-rabbit peroxidase-conjugated secondary antibodies (Jack-
son ImmunoResearch, Cambridgeshire, UK).
Animals—Four-week-old male ob/ob mice and their lean,
wild-type male C57BL/6J controls were purchased from
Charles River (Calco, Italy). In compliance with the Principles
of Laboratory Animal Care (National Institutes of Health pub-
lication 86-23), mice were housed at constant room tempera-
ture (23 °C) in a 12-h light/dark cycle (7 a.m. to 7 p.m.) receiving
standard chow andwater ad libitum. Mice were sacrificed at 14
weeks of age in the fasted state.
Generation of Human SOCS3 Expression Construct and Ret-
roviral Infection in HepG2 Cells—Full-length human SOCS3
(accession no. 003955) was generated by polymerase chain
reaction (PCR) using the following primers: 5-CGGGATCC-
ATGGTCACCCACAGCAAGTTTCC-3 and 5-CGCTCGA-
GTTAAAGCGGG GCATCGTACTGG-3 and the Expand
High-Fidelity PCR System (Roche Diagnostics). The sequence
of the polymerase chain reaction-generated construct was con-
firmed by sequencing (Primm, Milan, Italy). Retroviral expres-
sion plasmid was then constructed using the pBM-IRES-PURO
(28) expressing the puromycin resistance gene as a selectable
second cistron gene, generated from the original pBM-IRES-
EGFP, generously provided by Garry P. Nolan (Stanford Uni-
versity, Stanford, CA). Retroviral infections of HepG2 were
performed as previously described (28, 29). A polyclonal popu-
lation of HepG2 control and SOCS3-overexpressing cells has
been then selected with 10 g/ml puromycin.
Transfection of siRNA—ON-TARGET plus SMART pool
siRNAdirected to STAT3 and SOCS3 or scramble control were
purchased from DharmaconTM (Carlo Erba Reagents, Milan,
Italy). Transfections were performed as previously described
using SilentFectTM Lipid Reagent (Bio-Rad) according to the
manufacturer’s protocol (30, 31). HepG2 cells were seeded at a
density of 6 105/well (6 well tray) the day before the transfec-
tion in completedmedium. Cells were then transfected with 20
nM siRNA for 48 h, then the medium was replaced with MEM
containing 5% LPDS  TNF- for an additional 24 h before
performing the quantitative real time PCR (qPCR) or WB
analysis.
Synthesis of Total Cholesterol—Cholesterol biosynthesis was
estimated by measuring the incorporation of [14C]acetate into
cellular cholesterol, as previously described (32).
Evaluation of Intracellular TG and Cholesterol Levels—Total
cellular lipids were extracted with hexane/isopropyl alcohol
3:2, and TG and cholesterol contents were determined with
enzymatic assays (HORIBA ABX, Montpellier, France).
ELISAAssay—Conditionedmedia was cleared by centrifuga-
tion (13,000 rpm for 10 min) and store at20 °C. The amount
of apolipoprotein B (apoB) (Vinci-Biochem, Firenze, Italy) and
PCSK9 (R&D System, Minneapolis, MN) was then quantified
by using the ELISA assays according tomanufacturer’s instruc-
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tions. The values were normalized with total cell protein con-
tents, extracted from the cell monolayer, and determined by
BCA assay (Thermo Fischer Scientific).
Luciferase Reported Promoter Activities Assay—The plasmid
pGL3-PCSK9-D4 contains the 5 flanking region of the PCSK9
gene from 440 to 94 relative to the ATG start codon as
previously described (33). To measure the PCSK9 promoter
activity, HepG2 cells were seeded in 48-well plates at a density
of 8 105 cells per well. On the next day cells were transiently
transfected with pGL3-PCSK9-D4 plasmids with turbofect re-
agent (Carlo Erba Reagents), and 48 h post transfection cells
were incubated with serum-free medium in the presence or
absence of insulin (107 M) for an additional 24 h. Luciferase
activities weremeasured by usingNeolite reagent (PerkinElmer
Life Sciences according to the manufacturer’s instructions.
pCMV- vector, encoding for -galactosidase (Clontech,
Mountain View, CA) was cotransfected as the internal control.
-Galactosidase activity was assayed as described (34). Lucifer-
ase activitywas normalized to the-galactosidase activity of the
cotransfected pCMV- construct.
RNA Preparation and Quantitative Real Time PCR—Total
RNA was extracted with the iScript Sample Preparation Buffer
(Bio-Rad) cDNA synthesis preparation reagents (Bio-Rad)
according to manufacturer’s instructions. Reverse tran-
scription-polymerase first-strand cDNA synthesis was per-
formed by using the iScript cDNA synthesis Kit (Bio-Rad).
qPCR was then performed by using the Kit Thermo SYBR
Green/ROX qPCRMaster Mix (Carlo Erba Reagents) and spe-
cific primers for selected genes. Primer sequences used for
qPCR analysis are shown in Table 1. The analyses were per-
formed with the ABI Prism 7000 Sequence Detection System
(Applied Biosystems; Life Technologies Europe BV, Milan,
Italy). PCR cycling conditions were as follows: 94 °C for 3 min,
40 cycles at 94 °C for 15 s, and 60 °C for 1 min. Data were
expressed asCt values andused for the relative quantification of
targets with the Ct calculation.
Western Blot Analysis—Total cytosolic protein extracts of
HepG2 and HepG2SOCS3 were obtained by collecting cells in
150 l of Mammalian Protein Extraction Reagents (Thermo
Fisher Scientific) containing a mixture of protease and phos-
phatase inhibitors (Roche Diagnostics). 20 g of proteins and
a molecular mass marker (Novex Sharp Protein Standard,
InvitrogenTM; Life Technologies Europe BV)were separated on
4–12% sodiumdodecylsulfate-polyacrylamide gel (SDS-PAGE;
Novex NuPAGE 4–12% Bis-Tris Mini Gels, InvitrogenTM;
Life Technologies) under denaturing and reducing conditions.
Proteins were then transferred to a nitrocellulosemembrane by
using the iBlotTM Gel Transfer Device (InvitrogenTM; Life
Technologies). The membranes were washed with Tris-buff-
ered saline-Tween 20 (TBS-T), and nonspecific binding sites
were blocked in TBS-T containing 5% (BSA; Sigma) for 90 min
at room temperature. The blots were incubated overnight at
4 °Cwith a diluted solution (5%BSAor nonfat driedmilk) of the
following human primary antibodies: anti-PCSK9 (1:100), anti
SREBP-2 (1:200), anti-pAKT (1:100), anti-AKT (1:1,000), anti-
pSTAT3 (1:10,000), anti-pIRS-1 (1:5,000), anti-SCD-1 (1:500),
anti-STAT3 (1:1,000), anti-SREBP-1a (1:500), anti-SOCS3
(1:100), anti-HMG-CoA reductase (1:500), anti HNF-1
(1:1,000), and anti--tubulin (1:2,000). Membranes were
washed with TBS-T and then exposed for 90 min at room tem-
perature to a diluted solution (5% nonfat dried milk) of the
secondary antibodies. Immunoreactive bands were detected by
exposing the membranes to ClarityTM Western ECL chemilu-
minescent substrates (Bio-Rad) for 5 min, and images were
acquired with a ChemiDocTM XRS system (Bio-Rad). Densito-
metric readingswere evaluated using the ImageLabTM software
as previously described. The values of the phosphorylated pro-
teins were normalized to those of the corresponding constitu-
tive forms to express arbitrary units of relative expression.
Analysis of the Data—Statistical analysis was performed
using the Prism statistical analysis package Version 6.0
(GraphPad Software, San Diego, CA). Data are given as the
mean  S.D. of three independent experiments. When possi-
ble, p values were determined by Student’s t test. Otherwise,
differences between treatment groups were evaluated by one-
way ANOVA. A probability value of p  0.05 was considered
statistically significant.
Results
TNF- Induced SOCS3 and PCSK9 in HepG2 Cells—Release
of proinflammatory cytokines such as TNF- and IL-6 from
adipocytes of obese subjects with IR has been shown to activate
the JAK/STAT pathway at the hepatic levels and induce, either
directly or indirectly, the transcription of different target genes
including SOCS proteins (6, 7). In agreement with these obser-
vations we found that the incubation of hepatic cell line HepG2
withTNF- induced the expression of SOCS3mRNA in a time-
and concentration-dependent manner (Fig. 1A), reaching the
maximal induction after 24 h of incubation at the concentration
of 10 ng/ml. This latter resulted in 3-fold induction of SOCS3
protein, evaluated by WB analysis (Fig. 1A). Under the same
experimental conditions, TNF- induced both PCSK9 mRNA,
although to lower extent (Fig. 1B), and PCSK9 protein (41%),
as determined byWB analysis (Fig. 1B). Transfection of HepG2
cells with specific siRNA significantly down-regulated protein
expression of STAT3 andSOCS3 (Fig. 1C). siRNASTAT3 com-
TABLE 1
Primer sequence utilized for the qPCR analysis
Human Sequences
Fatty acid synthase forward 5-GCAAATTCGACCTTTCTCAGAAC-3
Fatty acid synthase reverse 5-GGACCCCGTGGAATGTCA-3
HMG-CoA reductase forward 5-CTTGTGTGTCCTTGGTATTAGAGCTT-3
HMG-CoA reductase reverse 5-GCTGAGCTGCCAAATTGGA-3
SOCS3 forward 5-GACCAGCGCCACTTCTTCAC-3
SOCS3 reverse 5-CTGGATGCGCAGGTTCTTG-3
SREBP-1 forward 5-CGGAACCATCTTGGCAACA-3
SREBP-1 reverse 5-GCCGGTTGATAGGCAGCTT-3
SREBP-2 forward 5-AGCTGGTCTGTGAAG-3
SREBP-2 reverse 5-CGCAATGGGGTCAGC-3
HNF-1 forward 5-TGGCGCAGCAGTTCACCCAT-3
HNF-1 reverse 5-TGAAACGGTTCCTCCGCCCC-3
LDLR forward 5-GTGTCACAGCGGCG-3
LDLR reverse 5-CGCACTCTTTGATG-3
PCSK9 forward 5-CCTGCGCGTGTCAACT-3
PCSK9 reverse 5-GCTGGCTTTTCCGAAACTC-3
SCD-1 forward 5-CTATACCACCACCACCACCA-3
SCD-1 reverse 5-GGGCATCGTCTCCAACTTAT-3
apoB forward 5-GCAGACTGAGGCTACCATGA-3
apoB reverse 5-AGGATTGTTCCGAGGTCAAC-3
Mouse
PCSK9 forward 5-AACCTGGAGCGAATTATCCCA-3
PCSK9 reverse 5-TTGAAGTCGGTGATGGTGACC-3
STAT3-dependent Regulation of PCSK9
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pletely blocked the induction of SOCS3 by TNF- (Fig. 1D). A
similar effect was observed on the expression levels of PCSK9,
where siRNA to either SOCS3 or STAT3 blocked the effect of
TNF- (Fig. 1E). These results suggest the possibility that
TNF- induces PCSK9 by inducing the SOCS3 expression.
SOCS3 Overexpression Induced PCSK9 in HepG2—To fur-
ther investigate the role of SOCS3 on PCSK9 expression, we
generated a retrovirally transducedHepG2 cell line with a plas-
mid encoding human SOCS3 (HepG2SOCS3). After puromycin
selection, the mRNA and protein overexpression of exogenous
human SOCS3 were evaluated by qPCR and WB analyses,
respectively. HepG2SOCS3 cells were compared with HepG2
transduced with empty retroviral vector encoding only the
puromycin resistance gene. As shown in Fig. 2A, retroviral
transduction determined 	90-fold induction of mRNA of
SOCS3 that translated into a 70% increase of protein SOCS3
(Fig. 2B). The overexpression of SOCS3 abrogated basal STAT3
phosphorylation state (Fig. 2C).
HepG2SOCS3 cells show higher levels of PCSK9 mRNA
(3.48  0.35-fold; Fig. 2D) and increased amounts of cellular
and secreted PCSK9 (1.53-fold and 2.18  0.38-fold, respec-
tively; Fig. 2, E and F). Because SOCS3 has been shown to be
up-regulated in animalmodels of obesity (6), we then evaluated
themRNA levels of PCSK9 and SOCS3 in the liver of ob/ob and
wild-type C57BL/6 control mice. The ob/ob mice expressed
higher levels of SOCS3 (6.46 4.8-fold), and this conditionwas
associated with a significant induction of PCSK9 (2.03 1.54-
fold) (Fig. 2,G andH). The inhibition of SOCS3 and STAT3 by
siRNA resulted in an opposite effect on PCSK9 mRNA levels,
with a significant reduction after transfection with siRNA
SOCS3 and an induction with siRNA STAT3 (Fig. 2I).
We then investigated the effect of SOCS3 on PCSK9 pro-
moter activity in HepG2 and HepG2SOCS3 transfected with the
luciferase reporter construct pGL3-PCSK9-D4 (33). This plas-
mid contains the 5-flanking region of the PCSK9 gene, from
nucleotide 440 to 94 (relative to the ATG start codon), in
FIGURE 1. TNF- induced SOCS3 and PCSK9 in HepG2 cells. A and B, HepG2 cells were seeded in MEM, 10% FCS and the day after incubated with MEM
supplemented with 10% LPDS for 6 h and 24 h in the presence or absence of different concentrations of TNF- (0.1, 1, and 10 ng/ml). At the end of the
incubation the total RNA was extracted, and mRNA levels of SOCS3 and PCSK9 were determined by qPCR. Insets of panels A and B SOCS3 and PCSK9 protein
expression were evaluated by WB analysis from total protein extracts of HepG2 cells incubated for 24 h with 10 ng/ml TNF-. -Tubulin was used as loading
control. C, HepG2 cells were seeded in MEM, 10% FCS and the day after transfected with siRNA scramble, STAT3, and SOCS3. After 48 h the medium was
replaced with MEMwith 10% LPDS. After an additional 24 h the protein expression of STAT3 and SOCS3 and -tubulin were evaluated by WB analysis. D and
E, cells were incubated under the same experimental conditions described for panels A and B in the presence or absence of 10 ng/ml TNF-during the last 24 h
of incubation in MEM with 10% LPDS. At the end of the incubation the total RNA was extracted, and mRNA levels of SOCS3 and PCSK9 were determined by
qPCR. Differences between treatmentswere assessed by Student’s t test and one-way ANOVA (when necessary): *, p 0.05; **, p 0.01; ***, p 0.001.
STAT3-dependent Regulation of PCSK9
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front of the luciferase coding sequence. The relative luciferase
activity of the PCSK9 promoter was not affected by the expres-
sion of SOCS3 in HepG2 cells (Fig. 2L). A similar response was
observed by using the D4 construct containing the mutation of
sterol regulatory element (SRE), whereas the mutation of
HNF-1 site determined a significant increase of the promoter
activity in HepG2SOCS3 cells, although the overall transcrip-
tional activity was almost abolished (Fig. 2L).
To further investigate the effect of SOCS3 on PCSK9mRNA
induction, we determined the involvement of the SREBP fac-
tors by incubating HepG2 with 25-OH cholesterol (inhibitor of
both SREBP-1 and SREBP-2) (32) or fatostatin (amore selective
inhibitor of SREBP-1) (35). As shown in Fig. 3A, 25-OH choles-
terol completely down-regulated the PCSK9 mRNA levels in
both HepG2 and HepG2SOCS3. On the contrary, fatostatin
affected exclusively the induction of PCSK9 in HepG2SOCS3
(Fig. 3B). SOCS3 overexpression induced the processing from
the precursor to the active form of SREBP-1 (Fig. 3C). The acti-
vation of SREBP-2 was inhibited, with the accumulation of its
precursor and a reduction of the active form (Fig. 3C). In addi-
tion, HNF-1 protein (54%) and mRNA levels (2.87  0.98-
fold) were significantly induced in SOCS3-overexpressing cells
(Fig. 3,C andD). The incubation with the transcriptional activ-
ity inhibitor, actinomycin D, showed that in HepG2SOCS3 the
stability of PCSK9 mRNA was not affected compared with
HepG2 (Fig. 3E). Taken together, these results suggest that the
PCSK9 induction in response to SOCS3 overexpression is
mainly mediated by a transcriptional-regulated process.
Pharmacological Inhibition of JAK/STAT Pathway Induced
PCSK9—To further investigate the effect of STAT3 inhibition
on PCSK9 expression, HepG2 cells were incubated with non-
toxic concentration of STAT3-inhibitor MD77 (Fig. 4) (36).
FIGURE 2. SOCS3 overexpression induced PCSK9 in HepG2 cells. A, HepG2 cells were retrovirally transduced with empty retroviral vector or encoding for
human SOCS3. After puromycin selection the expression of SOCS3 mRNA was evaluated by qPCR in HepG2 and HepG2SOCS3 cultured in MEM supplemented
with 10% LPDS for 24 h. B, under the same experimental conditions SOCS3 expression was determined by WB analysis from total cell lysates using an
anti-SOCS3 antibody. The membrane was stripped and re-probed with anti--tubulin antibody as loading control. C, WB analyses with anti-phospho-STAT3
and anti-STAT3 were performed from the same samples described for panel B. D–F, HepG2 and HepG2SOCS3 cells were seeded in MEM, 10% FCS and the day
after incubated with MEM containing 10% LPDS for 24 h. D, PCSK9 mRNA was determined by qPCR. Intracellular (E) and secreted (F) PCSK9 levels were
evaluated by WB analysis and ELISA assay, respectively. For the determination of PCSK9 levels with WB analysis, the cells were incubated for 24 h under
serum-free conditions.G andH, PCSK9 and SOCS3mRNA expression levels (qPCR)were determined from total hepatic RNAofmale ob/ob (n
 5) and C57BL/6
controlmice (n
 5). I, HepG2 cells were seeded inMEM, 10%FCS and the day after transfectedwith siRNA scramble, SOCS3, and STAT3. After 48 h themedium
was replaced with MEMwith 10% LPDS. After an additional 24 h, the total RNAwas extracted, andmRNA levels of PCSK9 were determined by qPCR. L, HepG2
and HepG2SOCS3 cells were transfectedwith pGL3-PCSK9-D4 or pGL3-PCSK9-SREmut or pGL3-PCSK9-HNFmut. The day after the transfection themediumwas
replacedwithMEMcontaining10%LPDS, andafteranadditional24h luciferaseactivitiesweredeterminedbyNeolite reagent. Luciferaseactivitieswerenormalized
to the-galactosidase activity of the cotransfected pCMV- construct. Differences between groupswere assessed by Student’s t test. *p 0.05; **p 0.01; ***, p
0.001.
STAT3-dependent Regulation of PCSK9
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Incubation of HepG2 cells for 48 h with 107 M MD77 deter-
mined very similar cellular responses from those observed with
SOCS3 overexpression. In particular, incubation with MD77
induced fatty acid synthase (FAS; 2.93  1.28-fold; Fig. 4A),
PCSK9 (2.06  0.7-fold; Fig. 4B) and, only marginally, HMG-
CoA reductase (1.58 0.2-fold; Fig. 4C) with a not statistically
significant reduction of LDLR (45.3  24.7%; Fig. 4D). The
JAK inhibitor, JAK1, significantly increased FAS (1.56  0.05-
fold; Fig. 4E), PCSK9 (3.30 0.32-fold; Fig. 4F), andHMG-CoA
reductase (1.49  0.09-fold; Fig. 4G) and marginally reduced
the LDLR (43.2 24.2%; Fig. 4H). Consistent with the results
with HepG2SOCS3, no effect on PCSK9 promoter activity was
observed after 24 h of incubation with JAK1 (Fig. 4I). Taken
together, these results demonstrate that the inhibition of the
JAK/STAT pathway induces PCSK9 in HepG2 cells.
SOCS3 Overexpression Induced de Novo Lipogenesis in
HepG2Cells—In vivo evidence demonstrated the pivotal role of
SOCS3 and STAT3 on lipid metabolism and SREBP-1 tran-
scriptional activity (6, 7, 37). To verify that a similar response
also occurs in our experimental model, we determined the
mRNA levels of SREBP-1 target genes, such as FAS and SCD-1
and the levels of apoB. HepG2SOCS3 cells showed highermRNA
levels of FAS (3.59 0.40-fold; Fig. 5A) as well as that of SCD-1
gene (1.92  0.12-fold; Fig. 5B) and protein (3.81  0.75-fold;
Fig. 5C). Together with these changes, we observed a significant
increment of apoBmRNA (4.08 0.41-fold; Fig. 5D) and protein
in theconditionedmedia (3.470.09-fold;Fig. 5E).Accumulation
of intracellular TG levels (22.1  7.1 g/mg of protein versus
38.3  9.1 g/mg of protein; Fig. 5F) was seen in HepG2SOCS3,
with no significant changes in total cholesterol content (Fig. 5G).
In response to TNF-, we observed a significant induction of
SCD-1, apoB, and FAS mRNA levels (2.11 0.43, 1.60 0.33,
and 1.39  0.21-fold, respectively; Fig. 5, H–L). These
responseswere reversed inHepG2 cells transfectedwith siRNA
STAT3 (Fig. 5, H–L). Taken together, the overexpression of
SOCS3 induced the de novo lipogenesis and increased apoB
production in HepG2 cells, effects dependent on STAT3.
SOCS3Overexpression Did Not Affect the Cholesterol Biosyn-
thesis in HepG2—A series of experiments was performed to
determine the effect of SOCS3 on genes under the control of
SREBP-2, such as HMG-CoA reductase and LDLR. HMG-CoA
reductase mRNA was induced in HepG2SOCS3 cells (2.10 
0.66-fold; Fig. 6A); conversely, the LDLR mRNA levels were
reduced in response to SOCS3 overexpression (56% 21.6%;
Fig. 6B). These changes were not associated with significant
variation of HMG-CoA reductase protein level (Fig. 6C). The
lack of significant changes of HMG-CoA reductase was also
confirmed by the fact that the cholesterol biosynthesis was
not altered in HepG2SOCS3 cells compared with HepG2 cells
(Fig. 6D).
Effect of SOCS3 Overexpression on Insulin-induced PCSK9
Expression—To corroborate the pathophysiological relevance
of our observations, we then investigated the effect of SOCS3
overexpression on insulin signaling. As shown in Fig. 7A, in
response to insulin (107 M), a significant induction of IRS-1
Tyr896 and Akt Ser473 phosphorylations was observed in
HepG2. Overexpression of SOCS3 (HepG2SOCS3 cells) resulted
in a reduced activation of both IRS-1 (Fig. 7A) and AKT (Fig.
7B) in response to insulin. In accordance with previous studies
(38), ectopic expression of SOCS-3 appeared to elevate basal
FIGURE 3. SOCS3-dependent up-regulation of PCSK9 mRNA was mainly driven by a transcriptional mechanism. A–D, HepG2 and HepG2SOCS3 were
seeded in MEM, 10% FCS and the day after incubated with MEM containing 10% LPDS for 24 h in the presence or absence of 25-OH cholesterol (5 M; A) or
fatostatin (40M; B). The levels of PCSK9mRNAwere thendeterminedbyqPCR.C, the levels of SREBP-1, SREBP-2, andHNF-1weredeterminedbyWBanalysis.
Arrows indicate the active and the precursor forms SREBPs. Two different exposure timeswere utilized for the precursor and the active form of SREBP-2, which have
been shown in two different panels. HNF-1mRNA levels were determined by qPCR (D), and HepG2 and HepG2SOCS3 were incubated at the indicated times with
actinomycinD (5g/ml) and PCSK9mRNA, determined by qPCR (E) . Differences between treatmentswere assessed by Student’s t test and one-way ANOVA (when
necessary). *, p 0.05; **, p 0.01 HepG2 versusHepG2SOCS3; §, p 0.01 25-OH cholesterol versus untreated; #, p 0.01 fatostatin versus untreated.
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autophosphorylation, although this increase was not statisti-
cally significant.
Moreover, STAT3 phosphorylation was induced in response
to insulin in control cells (HepG2), whereas SOCS3 overexpres-
sion (HepG2SOCS3) determined an abrogation of this response
(Fig. 7C). As previously reported by Costet et al. (22), the incu-
bation of HepG2 cells with insulin (107 M) significantly
induced both PCSK9 secretion andmRNA (Fig. 8,A andB), and
the presence of SOCS3 further up-regulated the response to
insulin at the mRNA levels. However, this effect did not trans-
late to a further induction of PCSK9 secretion in the cultured
media, as determined by ELISA assay (Fig. 8A). Similarly, we
observed an additive effect of insulin and SOCS3 on the FAS
and SREBP-1 mRNA levels (Fig. 8, C and D) with no effect on
SREBP-2 and HMG-CoA reductase levels (Fig. 8, E and F).
Discussion
In this paper, we tested the hypothesis that the inhibition of
the JAK/STAT pathway by SOCS3 could influence the PCSK9
levels in hepatic cell line. The rationale of performing this study
is based on at least four previously reported observations. 1) In
clinical settings positive relationships of apoB-containing lipo-
proteins and PCSK9 have been observed (24–27). 2) SOCS3
overexpression in mice induces SREBP-1 transcriptional acti-
vation and de novo lipogenesis (6, 7). 3) PCSK9 has been shown
to be transcriptionally regulated by SREBP-1 and SREBP-2 (22,
23). 4) The adipokine resistin and insulin induce SOCS3 and
PCSK9 expression in cultured cell lines and animal models (5,
39–41).
The first novel aspect that we observed was the induction of
PCSK9 in response to the proinflammatory cytokine TNF-,
the same factor that efficiently induces SOCS3 and has been
implicated in chronic-inflammation associatedwith IR (42, 43).
To study the possible link between SOCS3 and PCSK9, we first
suppressed the expression of SOCS3 by siRNA in HepG2. By
using this approach we demonstrated that SOCS3 is required
for the TNF--driven induction of PCSK9. In addition, the
silencing of STAT3 blocked the induction of SOCS3, PCSK9,
apoB, and SCD-1 in response to TNF- (Figs. 1 and 5).
Although the effect of proinflammatory cytokines on genes reg-
FIGURE 4. Pharmacological inhibition of JAK/STAT pathway induced PCSK9 in HepG2 cells. HepG2 cells were seeded in MEM, 10% FCS and the day after
incubatedwithMEMcontaining10%LPDS for 24h in thepresenceor absenceof theSTAT3 inhibitorMD77 (107M) (A–D) or JAK inhibitor JAK1 (105M) (E–H).mRNA
levels of FAS (A and E), PCSK9 (B and F), HMG-CoA reductase (C and G), and LDLR (D and H) were determined by qPCR. I, HepG2 cells were transfected with pGL3-
PCSK9-D4orpGL3-PCSK9-SREmutorpGL3-PCSK9-HNFmut. Thedayafter the transfection themediumwas replacedwithMEMcontaining10%LPDSwithorwithout
JAK1(105M),andafteranadditional24hluciferaseactivitiesweredeterminedbyNeolitereagent.Luciferaseactivitieswerenormalizedtothe-galactosidaseactivity
of the cotransfected pRSV-galactosidase construct. Differences between groupswere assessed by Student’s t test. *, p 0.05; **, p 0.01.
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ulating the de novo lipogenesis has been previously described
(42, 44), our data proposes PCSK9 as a gene involved in lipid
metabolism regulated by proinflammatory cytokineTNF- in a
SOCS3-dependent manner. We then established a hepatic cell
line stably overexpressing SOCS3, the endogenous inhibitor of
STAT proteins, and consistently found to be up-regulated in
the liver of genetically and diet-induced obese animal (6, 7).
By WB analysis, we demonstrated that SOCS3 overexpres-
sion abrogated STAT3 phosphorylation and, thus, the JAK/
STAT pathway. By using this cellular model, we observed a
significant induction of both PCSK9 mRNA and protein. The
involvement of both JAK and STAT proteins was then con-
firmed by the use of selective pharmacological inhibitors, JAK-I
and MD77 (36). The suppression of STAT3 by siRNA induced
PCSK9, whereas the opposite effect was seen after the down-
regulation of SOCS3. In combination with the induction of
PCSK9, we also observed increased SREBP-1 processing and a
significant up-regulation of the key genes involved in the de
novo lipogenesis, such as FAS and the SCD-1 together with the
apoB mRNA, apoB, secretion, and intracellular TG. Interest-
ingly, we noticed that PCSK9 was up-regulated in the liver of
ob/ob mice together with SOCS3, possibly supporting the link
between these two genes as observed in cultured system. How-
ever, as STAT3 is regulated by a large number of cytokines, like
IL-6 and TNF- (45), further in vivo studies are needed to elu-
cidate the possible role of STAT3 in SOCS3-driven regulation
of PCSK9. The consistent and very significant induction of
apoB secretion confirmed the pivotal role of SOCS3 and the
related inflammatory pathway on hypertriglyceridemia. In
addition, our observation suggested a possible involvement of
PCSK9 on apoB production by hepatic cells and/or by the liver
of animal models previously described (46–48). For instance,
FIGURE 5. SOCS3 overexpression induced de novo lipogenesis in HepG2 cells. A, B, andD, HepG2 and HepG2SOCS3 cells were seeded inMEM, 10% FCS and
thedayafter incubatedwithMEMsupplementedwith10%LPDS for 24h.mRNA levels of FAS, SCD-1, andapoBwereevaluatedbyqPCRanalysis fromtotal RNA.
C, under the same experimental conditions, the SCD-1 expression was determined byWB analysis from total protein extracts. E, HepG2 and HepG2SOCS3 were
cultured in serum-free medium for 24 h in the presence or absence of 107 M insulin, conditioned media was then collected, and apoB concentrations
were determinedby ELISA assay. F andG, under the sameexperimental conditions described for panel A, the intracellular TG and cholesterol (Chol.) levelswere
determined in HepG2 and HepG2SOCS3 by using an enzymatic assay. The values were normalized for total protein content. H–I, HepG2 cells were seeded in
MEM, 10% FCS and the day after transfected with siRNA scramble (scr.) and STAT3. After 48 h the medium was replaced with MEM with 10% LPDS in the
presence or absence of 10 ng/ml TNF-. After an additional 24 h, the total RNAwere extracted, andmRNA levels of SCD-1, apoB, and FASwere determined by
qPCR. Differences between HepG2 and HepG2SOCS3 were assessed by Student’s t test, and one-way ANOVA (when necessary). *, p 0.05; **, p 0.01; ***, p
0.001.
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the physical interaction between PCSK9 and apoB has been
shown to increase apoB production, possibly through the inhi-
bition of intracellular apoB degradation (48). Our evidence fur-
ther delineates the potential link between PCSK9 and apoB by
demonstrating that the inhibition of the JAK/STATpathway by
SOCS3 is a common determinant of their increased production
and secretion.Notably, recent findings suggest that PCSK9may
directly induce apoB mRNA levels in enterocytes (49). It is,
therefore, possible to speculate that SOCS3 could activate a
positive feedback loop by increasing the expression levels of
PCSK9, which in turn determines the induction of apoB
secretion.
Previous studies have established the SREBP-dependent
transcriptional activation of PCSK9. Indeed, similarly to the
LDLR and other cholesterol-regulated genes, the proximal
region of the PCSK9promoter contains an SRE-1motif (22, 50).
In addition, two independent studies have demonstrated that
insulin, by inducing SREBP-1c activity, induces PCSK9 both in
vitro and in vivo (22, 41). We confirmed this evidence at both
mRNA and protein levels, and the combination of SOCS3 and
insulin determined a further induction of de novo lipogenesis
genes, SREBP-1, and PCSK9, with no additive effect on PCSK9
secretion. These results are in agreement with previous studies
showing that the inhibition of STAT proteins by SOCS3 sup-
presses the transcription of SREBP-1 (7). In our study the tran-
scriptional activation of SREBP-1 was demonstrated by the
induction of key genes involved in the lipid synthesis, such as
FAS and SCD-1, whereas SREBP-2 appears to be unaffected by
SOCS3 for at least three reasons. The cholesterol biosynthesis
was not altered; an opposite regulation of two genes mainly
regulated by SREBP-2 was observed (HMG-CoA reductase and
LDLR), and the processing from the precursor to the active
form of SREBP-2 was not induced in response to SOCS3 over-
expression. The involvement of SREBPs was then demon-
strated by the fact that the incubation with 25-OH cholesterol,
which completely inhibits their activity, abolished PCSK9
expression. The contribution of SREBP-1, over the SREBP-2, in
the regulation of PCSK9 was further corroborated by using
fatostatin, a selective SREBP-1 inhibitor (35), which completely
suppressed the PCSK9 mRNA levels in HepG2SOCS3. The
involvement of HNF-1 on PCSK9 transcriptional regulation
has been previously demonstrated (33, 51). In the present study
we cannot exclude the involvement of HNF-1 in SOCS3-me-
diated PCSK9 induction as both protein and mRNA were
increased. Moreover, the luciferase assay with the PCSK9 pro-
moter region having either the HNF-1 or SRE site mutated was
drastically suppressed. These data suggest a mutual require-
ment of both SREBP andHNF-1 on transcriptional regulation
of PCSK9 (33).
The effect of SOCS3 on PCSK9 transcription, analyzed in
HepG2 and HepG2SOCS3, transiently expressing the PCSK9
promoter-driven luciferase reporters PCSK9-D4 (33), found,
unexpectedly, that this functional promoter was unresponsive
to SOCS3 overexpression (Fig. 2L). These results suggest that
the SOCS3 response sequences could possibly locate upstream
of the promoter region considered. In this regard it is important
to mention that the link between JAK/STAT pathway and
PCSK9 has been previously investigated in the same cell line by
the use of the cytokine oncostatin M (52). Similar to our study,
oncostatin M did not affect the PCSK9 promoter activity (52).
Because previous studies have shown that PCSK9 transcription
is controlled through cis regulatory elements located in the
proximal promoter region of the PCSK9 gene where the Sp1
sites and HNF1 and SRE-1 are located (23, 33, 51) we utilized
also a PCSK9-D4 containing a mutation for the HNF-respon-
sive element. Under this condition we detected a significant
increase of the promoter activity in HepG2SOCS3 cells. These
observation potentially related to the SREBPpathway, activated
in response to STAT inhibition, although the overall activity
was very low and potentially not responsible for the induction
of PCSK9 mRNA levels (7). This effect was also not confirmed
with the incubation of the JAK inhibitor, most likely because of
the minor inhibition of the pathway in comparison with the
complete block after SOCS3 overexpression.
We also exclude a SOCS3 effect on mRNA stability in the
induction of PCSK9, as incubation with the transcriptional
inhibitor actinomycin D did not affect mRNA stability com-
pared with HepG2. Hence, additional analysis is required to
better define the effect of SOCS3 on the transcriptional regula-
tion of PCSK9. Several studies have described the effect of
SOCS proteins on insulin signaling (1, 43, 53). Although the
observations may differ by the cell type and by the time consid-
ered, the majority of the studies suggests that SOCS proteins
control insulin action by reducing the expression of IRS pro-
teins (1, 43, 53). Indeed, in our experimental conditions SOCS3
FIGURE 6. Cholesterol biosynthesis was not influenced by SOCS3 in
HepG2 cells.A and B, HepG2 andHepG2SOCS3 cells were seeded inMEM, 10%
FCS and the day after incubatedwithMEM containing 10% LPDS for 24 h and
HMG-CoA reductase, and LDLR mRNA was determined by qPCR (A and B,
respectively). C, under the same experimental conditions, HMG-CoA reduc-
tase (red.) expressionwas assessed byWB analysis from total protein extracts.
D, HepG2 andHepG2SOCS3 were cultured inMEM containing 10% LPDS in the
presence of [14C]acetate. After 48 h [14C]acetate incorporation into cellular
cholesterol was evaluated. Each bar represents the mean S.D. of triplicate
dishes. Differences between HepG2 and HepG2SOCS3 were assessed by
Student’s t test. *, p 0.05.
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overexpression reduced both IRS-1 and Akt phosphorylation
in response to insulin. Moreover, insulin stimulation of
HepG2SOCS3 determined a further induction of genes related to
de novo lipogenesis (FAS and SREBP-1) as well as PCSK9.
Although this finding has been obtained in in vitro, it is con-
ceivable to hypothesize a functional contribution of PCSK9
on the hypertriglyceridemic condition observed in type 2
diabetes mellitus and obesity. Indeed, PCSK9 directly affects
the VLDR expression at the adipose tissue determining the
accumulation of visceral adipose tissue inmice (54). For such
an effect PCSK9-deficient mice show adipocyte hypertro-
phy, enhanced in vivo fatty acid uptake, and ex vivo triglyc-
eride synthesis (54).
In conclusion, in the present study we provide evidence for
the JAK/STAT-dependent expression of PCSK9 in the hepatic
cell line, suggesting the potential molecular basis of the direct
relationship between PCSK9 and TG levels observed in clinical
trials (24–27).
FIGURE 7. Effect of SOCS3 on insulin-induced IRS-1, Akt, and STAT3 phosphorylation. A–C, HepG2 and HepG2SOCS3 were seeded in MEM, 10% FCS and
starved overnight with serum-free medium before stimulation with insulin (107 M) for 5 and 10 min. WB analysis was then performed from total protein
extracts by using anti-pIRS-1, anti-pAkt, anti-pSTAT3, anti-STAT3, and anti--tubulin antibodies. Densitometric analysis was than evaluated using the
ImageLabTM software. Differences between groups were assessed by one-way ANOVA.
FIGURE8.Effect of insulinonPCSK9expression inHepG2SOCS3.A–F, HepG2andHepG2SOCS3 cellswere seeded inMEM, 10%FCSand theday after incubated
in serum-free medium for 24 h in the presence or absence of insulin (107 M). A, at the end of the incubation the PCSK9 levels in the conditioned media were
evaluated by ELISA assay, and mRNA levels of PCSK9, FAS, SREBP-1, SREBP-2, and HMG-CoA reductase were determined by qPCR (B–F). Differences between
groups were assessed by one-way ANOVA.
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